TACC3 and cancer: Among those, p21 and APAF1 are known to be direct targets of p53 [46, 47], suggesting that blocking NuRD complex via TACC3 inhibition can activate the transcription of tumor suppressors even in the absence of functional p53, e.g., in tumors with CA.